Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

JM Middeke; M Fang; Jan Cornelissen; B Mohr; FR Appelbaum; M Stadler; J Sanz; H Baurmann; G Bug; K Schafer-Eckart; U Hegenbart; T Bochtler; C Rollig; F Stolzel; RB Walter; G Ehninger; M Bornhauser; Bob Löwenberg; J Schetelig

doi:10.1182/blood-2013-12-544957

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

JM Middeke, M Fang, Jan Cornelissen, B Mohr, FR Appelbaum, M Stadler, J Sanz, H Baurmann, G Bug, K Schafer-Eckart, U Hegenbart, T Bochtler, C Rollig, F Stolzel, RB Walter, G Ehninger, M Bornhauser, Bob Löwenberg, J Schetelig

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

50 Citations (Scopus)

Abstract

Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl (17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.

Original language	Undefined/Unknown
Pages (from-to)	2960-2967
Number of pages	8
Journal	Blood
Volume	123
Issue number	19
DOIs	https://doi.org/10.1182/blood-2013-12-544957
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2013-12-544957

http://hdl.handle.net/1765/55717

Cite this

Middeke, JM., Fang, M., Cornelissen, J., Mohr, B., Appelbaum, FR., Stadler, M., Sanz, J., Baurmann, H., Bug, G., Schafer-Eckart, K., Hegenbart, U., Bochtler, T., Rollig, C., Stolzel, F., Walter, RB., Ehninger, G., Bornhauser, M., Löwenberg, B., & Schetelig, J. (2014). Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood, 123(19), 2960-2967. https://doi.org/10.1182/blood-2013-12-544957

@article{90dd0c0a5a7b46718890f6e8c45ef5a4,

title = "Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation",

abstract = "Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl (17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.",

author = "JM Middeke and M Fang and Jan Cornelissen and B Mohr and FR Appelbaum and M Stadler and J Sanz and H Baurmann and G Bug and K Schafer-Eckart and U Hegenbart and T Bochtler and C Rollig and F Stolzel and RB Walter and G Ehninger and M Bornhauser and Bob L{\"o}wenberg and J Schetelig",

year = "2014",

doi = "10.1182/blood-2013-12-544957",

language = "Undefined/Unknown",

volume = "123",

pages = "2960--2967",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "19",

}

Middeke, JM, Fang, M, Cornelissen, J, Mohr, B, Appelbaum, FR, Stadler, M, Sanz, J, Baurmann, H, Bug, G, Schafer-Eckart, K, Hegenbart, U, Bochtler, T, Rollig, C, Stolzel, F, Walter, RB, Ehninger, G, Bornhauser, M, Löwenberg, B & Schetelig, J 2014, 'Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation', Blood, vol. 123, no. 19, pp. 2960-2967. https://doi.org/10.1182/blood-2013-12-544957

TY - JOUR

T1 - Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

AU - Middeke, JM

AU - Fang, M

AU - Cornelissen, Jan

AU - Mohr, B

AU - Appelbaum, FR

AU - Stadler, M

AU - Sanz, J

AU - Baurmann, H

AU - Bug, G

AU - Schafer-Eckart, K

AU - Hegenbart, U

AU - Bochtler, T

AU - Rollig, C

AU - Stolzel, F

AU - Walter, RB

AU - Ehninger, G

AU - Bornhauser, M

AU - Löwenberg, Bob

AU - Schetelig, J

PY - 2014

Y1 - 2014

N2 - Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl (17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.

AB - Patients with acute myeloid leukemia (AML) and abnormalities of chromosome 17p (abnl (17p)) are at high-risk of treatment failure. Poor outcomes have been reported with conventional chemotherapy. To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with abnl(17p) AML, we analyzed the results of patients with this abnormality who received an allogeneic HSCT between January 2000 and December 2010 in 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for Adults in the Netherlands, Study Alliance Leukemia, German Cooperative Transplant Study Group). Data of 201 patients with a median age of 54 years were evaluable. At the time of analysis, 30 patients were alive with a median follow-up of 30 months. The 3-year probability of overall survival (OS) was 15% (95% confidence interval [CI], 10-20). The cumulative incidence of relapse at 3 years was 49% (95% CI, 42-56). Notably, almost 70% of all relapses occurred within the first 6 months after HSCT. Patients who were transplanted in first complete remission (CR1) had superior OS compared with those with advanced disease (22% vs 9%, P < .001). Our findings confirm the high-risk of treatment failure in abnl(17p) AML even after allogeneic HSCT in CR1. Although allogeneic HSCT remains a valid option in CR1, alternative treatment strategies are needed for the remaining patients.

U2 - 10.1182/blood-2013-12-544957

DO - 10.1182/blood-2013-12-544957

M3 - Article

VL - 123

SP - 2960

EP - 2967

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -